FDA will review risk of oral contraceptives containing drospirenone

Article

FDA has announced that it will review the safety of oral contraceptives (OCs) containing the progestin drospirenone after 2 recent studies in the British Medical Journal (2011;340:d2139 and 2011;340:d2151) suggested that they might cause more blood clots than birth control pills containing levonorgestrel.

FDA has announced that it will review the safety of oral contraceptives (OCs) containing the progestin drospirenone after 2 recent studies in the British Medical Journal (2011;340:d2139 and 2011;340:d2151) suggested that they might cause more blood clots than birth control pills containing levonorgestrel.

The studies reported a 2- to 3-fold higher risk of venous thromboembolic events (including deep vein thrombosis and pulmonary embolism) among women using OCs with drospirenone compared with levonorgestrel. Previous studies of blood clots associated with drospirenone produced conflicting findings. FDA has commissioned an 800,000-person study to examine the risks of drospirenone OCs and expects to have results later this year.

Drospirenone is found in OCs marketed under the brand names Beyaz, Safyral, Yaz (generics Gianvi and Loryna), and Yasmin (generics Ocella, Syeda, and Zarah). In addition to contraception, the pills are used to treat moderate acne and premenstrual dysphoric disorder, and to increase folate levels in women using oral contraceptives for birth control.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Maria Gallo, PhD, discusses high attendance at crisis pregnancy centers | Image Credit: © x.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.